scholarly journals Failure of fresh frozen plasma infusion and vitamin K to correct elevated international normalised ratio

2012 ◽  
Vol 2012 (jul12 2) ◽  
pp. bcr0820114635-bcr0820114635
Author(s):  
P. Vitish-Sharma ◽  
R. Shah ◽  
M. Anjari ◽  
J. Knowles ◽  
K. Qurashi
2012 ◽  
Vol 107 (04) ◽  
pp. 662-672 ◽  
Author(s):  
Leigh White ◽  
Mark Friedman ◽  
Christine Nichols ◽  
Jordan Menzin ◽  
Jan Hoesche ◽  
...  

SummaryThis study assessed the frequency and factors associated with failure to correct international normalised ratio (INR) in patients administered fresh frozen plasma (FFP) for warfarin-related major bleeding. This retrospective database analysis used electronic health records from an integrated health system. Patients who received FFP between 01/01/2004 and 01/31/2010, and who met the following criteria were selected: major haemorrhage diagnosis the day before to the day after initial FFP administration; INR ≥2 on the day before or the day of FFP and another INR result available; warfarin prescription within 90 days. INR correction (defined as INR ≤1.3) was evaluated at the last available test up to one day following FFP. A total of 414 patients met selection criteria (mean age 75 years, 53% male, mean Charlson score 2.5). Patients presented with gastrointestinal bleeding (58%), intracranial haemorrhage (38%) and other bleed types (4%). The INR of 67% of patients remained uncorrected at the last available test up to one day following receipt of FFP. In logistic regression analysis, the INR of patients who were older, those with a Charlson score of 4 or greater, and those with non-ICH bleeds (odds ratio vs. intracranial bleeding 0.48; 95% confidence interval 0.31–0.76) were more likely to remain uncorrected within one day following FFP administration. In an alternative definition of correction, (INR ≤1.5), 39% of patients’ INRs remained uncorrected. For a substantial proportion of patients, the INRs remain inadequately or uncorrected following FFP administration, with estimates varying depending on the INR threshold used.


Drugs ◽  
2019 ◽  
Vol 79 (14) ◽  
pp. 1557-1565 ◽  
Author(s):  
Robert Hill ◽  
Thang S. Han ◽  
Irina Lubomirova ◽  
Nikhil Math ◽  
Paul Bentley ◽  
...  

2017 ◽  
Vol 119 (3) ◽  
pp. 422-434 ◽  
Author(s):  
P.W. Collins ◽  
R. Cannings-John ◽  
D. Bruynseels ◽  
S. Mallaiah ◽  
J. Dick ◽  
...  

2017 ◽  
Vol 37 (2) ◽  
pp. 49-56
Author(s):  
Sherri Ozawa ◽  
Tiffany Nelson

Management of patients receiving anticoagulants is a major factor in achieving better outcomes. Anticoagulant therapy may need to be discontinued or rapidly reversed before urgent surgery or invasive procedures. In these situations, treatment with concentrated vitamin K, fresh frozen plasma, and/or clotting factors can achieve more rapid anticoagulant reversal than can drug discontinuation alone. Activated prothrombin complex concentrate is used to treat hemophiliac patients with acquired factor VIII inhibitors. Nonactivated prothrombin complex concentrates are used for anticoagulant reversal. The concentrates are effective within minutes of dosing, providing a nearly immediate decrease in the international normalized ratio. The concentrates are lyophilized powders that can be quickly reconstituted, do not require ABO blood typing before use, and contain 25 times the concentration of vitamin K–dependent clotting factors compared with fresh frozen plasma. Studies suggest that the concentrates are associated with better clinical end points than is fresh frozen plasma.


1976 ◽  
Vol 7 (5) ◽  
pp. 400-405
Author(s):  
Hiroshi INABA ◽  
Yasumasa SUGA ◽  
Osamu TATSUZAWA ◽  
Masatoshi KOSAKI ◽  
Toshio SEKIMOTO ◽  
...  

2003 ◽  
Vol 98 (6) ◽  
pp. 1391-1394 ◽  
Author(s):  
Wael I. Youssef ◽  
Fernando Salazar ◽  
Srinivasan Dasarathy ◽  
Timothy Beddow ◽  
Kevin Daniel Mullen

PEDIATRICS ◽  
1972 ◽  
Vol 50 (5) ◽  
pp. 693-701
Author(s):  
Robert P. Erickson ◽  
Robert Sandman ◽  
William van B. Robertson ◽  
Charles J. Epstein

Patients with Mucopolysaccharidosis II (Hunter's syndrome) were given short-term treatment with large infusions of fresh frozen plasma to evaluate recent claims of clinical and chemical improvement by such therapy. Clinical behavior, urine glycosaminoglycans, and skin, serum, and urine acid hydrolases were evaluated by single-blind techniques. There was no noticeable effect of fresh frozen plasma infusion on the performance of these patients. The total urinary excretion of glycosaminoglycans was not altered by the infusions and there was no change in the size of the glycosaminoglycan fragments. The abnormal skin activity levels of β-galactosidase, β-glucuronidase, and N-acetylglucosaminidase were unaltered three days after fresh frozen plasma infusion and, similarly, the abnormal levels of these enzymes in the serum persisted without significant change during the ten days of evaluation.


Sign in / Sign up

Export Citation Format

Share Document